Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Adipocyte Mesenchymal Stem Cells Derived Exosomes Improve Bleomycin-Induced Lung Fibrosis in Rat.

Ashtari A., Radan M., Dayer D., Soleimani MZ., Bayati V., Nejaddehbashi F.

Animal Study on Systemic / IV, published in Artif Organs (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Artif Organs (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41363035
DOI
10.1111/aor.70052

Abstract (original English)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease with limited treatment options. Although extracellular vesicles (EVs), such as exosomes, have shown therapeutic potential, their effectiveness and the best method of delivery are still under investigation. This study explored the therapeutic impact of exosomes derived from adipose-derived mesenchymal stem cells (ADMSCs-Exo) in a rat model of bleomycin-induced pulmonary fibrosis. Thirty Wistar rats were randomly divided into six groups: (1) Healthy control (Co), (2) Fibrosis control (Co/F), (3 and 4) Exosome inhalation groups treated with 250 or 500 μg/kg doses, and (5 and 6) Exosome injection groups receiving the same doses. Treatment effects were evaluated through lung tissue histopathology and analysis of key inflammatory biomarkers. The inhalation of ADMSCs-Exo at both doses significantly reduced levels of C-reactive protein (CRP), fibrinogen, pro-inflammatory cytokines, and histopathological signs of lung fibrosis compared to the fibrosis control group (p < 0.05). Notably, the inhalation route showed better therapeutic outcomes than systemic injection. The results suggest that inhalation delivery of ADMSCs-derived exosomes may provide a more effective and targeted strategy for treating pulmonary fibrosis compared to systemic administration.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsExosomesBleomycinRats, WistarMesenchymal Stem CellsRatsPulmonary FibrosisDisease Models, AnimalMaleLung

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research